Mon, 06th Jul 2020 18:19
ValiRx PLC - London-based clinical stage biotechnology company - Lays out strategy to build on portfolio of drug candidates in the oncology and women's health space. "The company plans to apply both intellectual and financial resources to each project and enable acceleration through pre-clinical development," ValiRx said.
Current stock price: 8.12 pence
Year-to-date change: down 46%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
(Alliance News) - ValiRx PLC on Thursday said that it has signed an evaluation deal with Imperial College London to look at research on novel therapeu...
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reporte...
(Alliance News) - ValiRx PLC on Tuesday said a requisition notice, which it received earlier in February, has been confirmed as invalid following lega...
(Sharecast News) - ValiRx announced the signing of a significant agreement with the University of Dundee and its Drug Discovery Unit (DDU) on Monday.
ValiRx PLC - Nuneaton, England-based life sciences company focused on early-stage cancer therapeutics - Signs agreement with Dundee University's drug ...
ValiRx (VAL)